Board at its meeting held today, i.e. May 11, 2026 has, inter alia, considered and approved the following:(i) audited Standalone and Consolidated Financial Results along with Audit Reports of the Company for the fourth quarter and year ended March 31, 2026;(ii) recommended final dividend of ₹ 10/- (100%) per equity share of face value of ₹ 10/- each to the shareholders for their approval at the ensuing Annual General Meeting of the Company;(iii) appointment of M/s. Walker Chandiok & Co LLP, Chartered Accountants as Statutory Auditor of the Company;(iv) re-appointment of M/s. Dhara Patel, peer reviewed Company Secretary Firm as the Secretarial Auditor of the Company;(v) appointment of M/s. Shah & Shah Associates, Chartered Accountants as Internal Auditor of the Company for the Financial Year 2026-27;(vi) re-appointment of M/s. Manish B. Analkat, as Cost Auditor of the Company for the Financial Year 2026-27;(vii) re-appointment of Dr. Kirtikumar Mehta (DIN: 00385658) as Non Executive Director and Chairman of the Company, for a term of five (5) consecutive Financial Years with effect from April 01, 2027
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts less than Nifty Microcap 250 and 4.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Corona Remedies Limited reported FY2026 standalone revenue of Rs. 1,403.18 crore, up 17.3% from Rs. 1,196.42 crore in FY2025. Net profit after tax grew 24% to Rs. 184.85 crore from Rs. 149.05 crore. EBITDA margin remained healthy at approximately 18.5%. The Board recommended a final dividend of Rs. 10 per share (100% payout), subject to shareholder approval at the AGM, with a record date of June 19, 2026. The company completed its IPO in December 2025 via an offer for sale. An exceptional charge of Rs. 19.10 crore was recorded due to the statutory impact of new Labour Codes (gratuity and compensated absences), reducing PAT by Rs. 14.29 crore post-tax. Short-term borrowings surged to Rs. 142.86 crore from Rs. 46.70 crore, largely secured against fixed deposits of Rs. 155.70 crore. Deloitte Haskins & Sells LLP (DHS) was replaced as statutory auditor by Walker Chandiok & Co LLP for five years from FY2026-27. Auditor's reports are unmodified.
Strong topline and bottom-line growth with 17.3% revenue growth and 24% PAT growth is positive. The auditor change from DHS to Walker Chandiok may draw attention but reports are clean. High short-term borrowing against fixed deposits warrants monitoring.